A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorIncyte Corporation
About this trial
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Eligibility criteria
Qualifiers
≥18 years old
Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol.
Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study.
ECOG performance status score of 0 or 1.
Disqualifiers
Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years.
Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy.
Has active autoimmune disease requiring systemic immunosuppression with corticosteroids.
Brain or CNS metastases untreated or that have progressed.
Trial design
Treatments tested in this trial
- INCA33890
- bevacizumab
- FOLFIRI
- FOLFOX
- Cetuximab
Treatment groups
408 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov